Table 1. . Baseline patient characteristics and factors associated with the use of varying intensity of chemotherapy.
| Variable (%) | Therapy | p-value | ||
|---|---|---|---|---|
| 10-day decitabine | Low intensity | High intensity | ||
| Age: | ||||
| – 60–69 (52.6%) | 13 (41%) | 10 (21%) | 88 (67%) | <0.0001 |
| – 70+ (47.4%) | 19 (59%) | 37 (79%) | 44 (33%) | |
| Sex: | ||||
| – Female (47.9%) | 23 (72%) | 22 (46.8%) | 56 (42%) | 0.0099 |
| – Male (52.1%) | 9 (28%) | 25 (53.2%) | 76 (58%) | |
| Race: | ||||
| – White (97.2%) | 30 (94%) | 47 (100%) | 129 (99%) | 0.0957 |
| – Non-white (2.8%) | 2 (6%) | 0 (0%) | 1 (<1%) | |
| Cytogenetic risk categories: | ||||
| – Adverse (40.2%) | 10 (35%) | 24 (57%) | 42 (36%) | 0.1270 |
| – Favorable (4.8%) | 1 (3%) | 2 (5%) | 6 (5%) | |
| – Intermediate (55.0%) | 18 (62%) | 16 (38%) | 70 (59%) | |
| Hematopoietic transplant comorbidity index: | ||||
| – 0 (31.3%) | 10 (33%) | 11 (24%) | 41 (33%) | 0.1996 |
| – 1–2 (28.3%) | 11 (37%) | 14 (31%) | 31 (25%) | |
| – 3–4 (30.3%) | 8 (27%) | 11 (24%) | 41 (33%) | |
| – 5+ (10%) | 1 (3%) | 9 (21%) | 10 (8%) | |
| Karnofsky score: | ||||
| – <60 (8.2%) | 1 (3.4%) | 5 (12.2%) | 10 (8%) | 0.507 |
| – 70–80 (35.9%) | 14 (48.3%) | 14 (34.2%) | 42 (33.6%) | |
| – 90–100 (55.9%) | 14 (48.3%) | 22 (53.6%) | 73 (58.4%) | |
| Diagnosis year: | ||||
| – 2000–2007 (36.2%) | 1 (3%) | 14 (30%) | 61 (46%) | <0.0001 |
| – 2008–2016 (63.8%) | 31 (97%) | 33 (70%) | 71 (54%) | |